Targeted Temperature Management in Spontaneous Intracerebral Hemorrhage: A Systematic Review
Standard
Targeted Temperature Management in Spontaneous Intracerebral Hemorrhage: A Systematic Review. / Fischer, Marlene; Schiefecker, Alois; Lackner, Peter; Helbok, Raimund; Beer, Ronny; Pfausler, Bettina; Schmutzhard, Erich; Broessner, Gregor.
In: CURR DRUG TARGETS, Vol. 18, No. 12, 2017, p. 1430-1440.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Targeted Temperature Management in Spontaneous Intracerebral Hemorrhage: A Systematic Review
AU - Fischer, Marlene
AU - Schiefecker, Alois
AU - Lackner, Peter
AU - Helbok, Raimund
AU - Beer, Ronny
AU - Pfausler, Bettina
AU - Schmutzhard, Erich
AU - Broessner, Gregor
PY - 2017
Y1 - 2017
N2 - Fever is common in neurocritical care patients and is associated with poor outcome. Targeted temperature management (TTM), i.e. therapeutic hypothermia or controlled normothermia, after acute brain injury has been studied as a neuroprotectant for several decades. In contrast to pharmacological agents with specific targets TTM affects multiple pathophysiological mechanisms and is primarily thought to attenuate secondary brain injury. Most promising results have been obtained from experimental studies on cerebral ischemia or traumatic brain injury showing beneficial effects of hypothermia on structural and functional outcome. A positive influence of hypothermia has been observed in animal models of spontaneous intracerebral hemorrhage (ICH) improving, among others, perihematomal edema, blood-brain barrier integrity, inflammation and thrombin-induced injury. However, results regarding functional outcome are conflicting. Little data is available on the effect of TTM in humans. Single-center observational studies have shown reduced perihematomal edema under mild hypothermia and an association with favorable outcome. Thus, results from ongoing, prospective randomized-controlled trials are highly anticipated.
AB - Fever is common in neurocritical care patients and is associated with poor outcome. Targeted temperature management (TTM), i.e. therapeutic hypothermia or controlled normothermia, after acute brain injury has been studied as a neuroprotectant for several decades. In contrast to pharmacological agents with specific targets TTM affects multiple pathophysiological mechanisms and is primarily thought to attenuate secondary brain injury. Most promising results have been obtained from experimental studies on cerebral ischemia or traumatic brain injury showing beneficial effects of hypothermia on structural and functional outcome. A positive influence of hypothermia has been observed in animal models of spontaneous intracerebral hemorrhage (ICH) improving, among others, perihematomal edema, blood-brain barrier integrity, inflammation and thrombin-induced injury. However, results regarding functional outcome are conflicting. Little data is available on the effect of TTM in humans. Single-center observational studies have shown reduced perihematomal edema under mild hypothermia and an association with favorable outcome. Thus, results from ongoing, prospective randomized-controlled trials are highly anticipated.
M3 - SCORING: Review article
C2 - 27397065
VL - 18
SP - 1430
EP - 1440
JO - CURR DRUG TARGETS
JF - CURR DRUG TARGETS
SN - 1389-4501
IS - 12
ER -